Articles

The company is investing in its Capsules and Health Ingredients Division to expand its capsule production capacity by 30 billion capsules annually. 

Lonza to Expand Capsule Production Capacity with $93 Million Investment

The 6th-generation Eclipse FFF system handles analytes such as proteins, polymers, viruses, gene vectors, and liposomal drug nanoparticles. 



Wyatt Technology Launches a New Line of Separation Instrumentation and Software for Analytes

The companies will work to accelerate the clinical development and manufacturing of the treatment, while determining its safety and efficacy.

Roche and Atea Pharmaceuticals Collaborate on Investigational Oral Antiviral for COVID-19

200 employees will be hired by the end of 2020, with 300 more planning to be hired by 2023. 

Roche Canada to Invest $500 Million and Create 500 New Jobs at its Canadian Global Pharma Technical Operations Site

The name change touches on the company’s AI and machine learning proficiencies, while including the expansion of the company’s mission to serve additional regulated industries including animal health, cosmetics, medical devices, specialty chemicals, nutraceuticals, and food and beverage.

Bigfinite Changes Name to Aizon

Vetter has moved into new headquarters located in Ravensburg, Germany, and plans to continue its long-term investment for corporate development.

Vetter Moves into New Headquarters and Continues Long-Term Investment

Donald Singer is senior microbiology technical consultant at Ecolab Life Sciences.

Subsequent guidance and manufacturing realities make portions of USP Chapters <62 >and <111> significantly less relevant. The authors suggest formal chapter revisions. 

Refining Microbiological Control for Non-Sterile Products

FDA issued guidance for applicants that must report annually on the status of postmarketing studies and clinical trials under section 506B of the FD&C Act.

Guidance on Annual Status Reports of Postmarketing Studies 

FDA sent a warning letter to LEC Custom Products for a variety of CGMP violations including use of inappropriate equipment and processes.

FDA Finds CGMP Violations at Canadian Facility 

Orgenesis has completed its previously announced acquisition of Koligo Therapeutics with the additional acquisition of Tissue Genesis’ cell isolation technology, Icellator.  

News